Strategic Funding Recent NIH P01 multimillion-dollar grant validating a strong research trajectory and potential for expanded collaborations; leverage it to position Intralytix for co-development deals, contract research, and grant-funded procurement opportunities with government and large biotech partners.

Phage Advantage Specialized bacteriophage-based solutions across environmental, food processing, and medical settings present cross-segment selling opportunities to food safety players, animal health companies, and environmental remediation firms seeking non-antibiotic pathogen control.

Industry Collaboration Historical partnerships with Lesaffre Yeast, AB Agri, and Ferring highlight a track record of collaboration; target similar large- and mid-size biotech, animal nutrition, and pharma players for co-development, licensing, or strategic investment discussions.

Growth Readiness Revenue in the tens of millions with a focused team and external funding indicates readiness for scaled pilot programs, production capacity partnerships, and distribution agreements to accelerate market entry in multiple regions.

Strategic Fit Small to mid-size team combined with niche, high-value ip and ongoing government funding makes Intralytix an attractive target for integrators and distributors in biotech, food safety, and healthcare supply chains seeking differentiated phage-based products.